Comparative Pharmacology
Head-to-head clinical analysis: ORSYTHIA versus ORTHO CEPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORSYTHIA versus ORTHO CEPT.
ORSYTHIA vs ORTHO-CEPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal aromatase inhibitor that selectively and reversibly inhibits aromatase, the enzyme responsible for converting androgens to estrogens, thereby reducing estrogen levels in tissues.
Combination oral contraceptive containing desogestrel and ethinyl estradiol. Inhibits ovulation by suppressing gonadotropin secretion; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial development.
400 mg orally twice daily
One tablet (0.15 mg desogestrel / 0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 placebo tablets (or 7 hormone-free days).
None Documented
None Documented
Terminal half-life ~12 hours (range 10-14 h); prolonged in renal impairment (up to 24-30 h).
Desogestrel: 23 hours (terminal), Etonogestrel active metabolite: 30 hours (terminal); clinical steady state after 7-10 days
Primarily renal (≥90% as unchanged drug); <5% biliary/fecal.
Renal: 50% (metabolites), Biliary/fecal: 40% (metabolites and unchanged drug), 10% unchanged in urine
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive